Catégorie : Cannabis et Réduction des Risques

Adolescent Treatment Admissions for Marijuana Following Recreational Legalization in Colorado and Washington, Jeremy Mennis, Gerald J Stahler, 2020

Adolescent Treatment Admissions for Marijuana Following Recreational Legalization in Colorado and Washington Jeremy Mennis, Gerald J Stahler Drug and Alcohol Dependence, 2020 May 1, 210, 107960. doi : 10.1016/j.drugalcdep.2020.107960 Abstract Introduction : There is concern that recreational marijuana legalization (RML) may lead to increased cannabis use disorder (CUD) among youth due to increased marijuana use. This study investigates whether adolescent substance use disorder treatment admissions for marijuana use increased in Colorado and Washington following RML. Methods : Annual data on 2008-2017 treatment admissions for marijuana use from the SAMHSA TEDS-A dataset for adolescents age 12-17 were used to model state treatment admissions trends. [...]

Lire la suite

The nephrologist’s guide to cannabis and cannabinoids, Joshua L. Rein, 2020

The nephrologist’s guide to cannabis and cannabinoids Joshua L. Rein   Purpose of review Cannabis (marijuana, weed, pot, ganja, Mary Jane) is the most commonly used federally illicit drug in the United States. The present review provides an overview of cannabis and cannabinoids with relevance to the practice of nephrology so that clinicians can best take care of patients. Recent findings Cannabis may have medicinal benefits for treating symptoms of advanced chronic kidney disease (CKD) and end-stage renal disease including as a pain adjuvant potentially reducing the need for opioids. Cannabis does not seem to affect kidney function in healthy individuals. However, renal function should be [...]

Lire la suite

New Data Show No Link Between Cannabis and Stroke Sue Hughes, Medscape.com, June 09, 2020

New Data Show No Link Between Cannabis and Stroke Sue Hughes Medscape.com, June 09, 2020 https://www.medscape.com/viewarticle/931988_print A new study that used admission urine toxicology tests to ascertain drug use found no independent association between recent cannabis use and the incidence of acute ischemic stroke. "Previous studies have shown conflicting data on cannabis use and stroke. Our study is a step forward in that we had quite a large population and we had an objective measure of marijuana use with the urine screen, whereas some previous studies have just relied on asking the patient about marijuana use," senior author Shreyas Gangadhara, MD, University of Mississippi Medical Center, Jackson, [...]

Lire la suite

Infection VIH et cannabinoides. Etat des lieux et pistes en recherche clinique, Roland Tubiana et Fabienne Caby, RESPADD – GRECC, 2019

Infection VIH et cannabinoides. Etat des lieux et pistes en recherche clinique Roland Tubiana et Fabienne Caby, 24e Rencontres du RESPADD - GRECC, "Usages Cliniques des Cannabinoïdes" 21 juin 2019   (...) Inflammation/ Activation immune et CB Chez les PVVIH traités efficacement, la consommation de CB a été associée: – À des niveaux moins élevés de marqueurs d’inflammation (L B TNF-α+ )/ activation immune (L TCD4+ et CD8+ HLA-DR+CD38+) – A une décroissance plus rapide du niveau d’ADN proviralVIH Mécanismes sous jacents CB (Cannabis Sativa) : > 60 cannabinoides, > 200 non cannabinoides • Cannabinoides: Composant capables d’activer la proteine G couplée aux récepteurs CB1 ou CB2 • Les 2 plus étudiés: Δ9-THC [...]

Lire la suite

Totality of the Evidence Suggests Prenatal Cannabis Exposure Does Not Lead to Cognitive Impairments : A Systematic and Critical Review, Ciara A. Torres et al., 2020

Totality of the Evidence Suggests Prenatal Cannabis Exposure Does Not Lead to Cognitive Impairments : A Systematic and Critical Review Ciara A. Torres, Christopher Medina-Kirchner, Kate Y. O'Malley and Carl L. Hardt Frontiers in Psychology, 2020, Vol 11, Art 816, 1-28. Doi : 10.3389/fpsyg.2020.00816   Background: Despite limited data demonstrating pronounced negative effects of prenatal cannabis exposure, popular opinion and public policies still reflect the belief that cannabis is fetotoxic. Methods: This article provides a critical review of results from longitudinal studies examining the impact of prenatal cannabis exposure on multiple domains of cognitive functioning in individuals aged 0 to 22 years. A literature search was [...]

Lire la suite

Prescription Opioid Distribution after the Legalization of Recreational Marijuana in Colorado, Amalie K. Kropp Lopez et al., 2020

Prescription Opioid Distribution after the Legalization of Recreational Marijuana in Colorado Amalie K. Kropp Lopez, Stephanie D. Nichols, Daniel Y. Chung, Daniel E. Kaufman, Kenneth L. McCall  and Brian J. Piper International Journal of Environmental Research and Public Health, 2020, 17, 3251 doi : 10.3390/ijerph17093251   Abstract : There have been dynamic changes in prescription opioid use in the US but the state level policy factors contributing to these are incompletely understood. We examined the association between the legalization of recreational marijuana and prescription opioid distribution in Colorado. Utah and Maryland, two states that had not legalized recreational marijuana, were selected for comparison. Prescription data reported to [...]

Lire la suite

Beneficial Effects of Cannabis on Blood Brain Barrier Function in HIV, Ronald J. ELLIS et al., 2020

Beneficial Effects of Cannabis on Blood Brain Barrier Function in HIV Ronald J Ellis  1 , Scott Peterson  2 , Mariana Cherner  1 , Erin Morgan  1 , Rachel Schrier  1 , Bin Tang  1 , Martin Hoenigl  1 , Scott Letendre  1 , Jenny Iudicello  1 Clinical infectious diseases, 2020 Apr 16, ciaa437. Doi : 10.1093/cid/ciaa437 Abstract Background: HIV infection leads to blood-brain barrier (BBB) dysfunction that does not resolve despite viral suppression on antiretroviral therapy and is associated with adverse clinical outcomes. In preclinical models, cannabis restores BBB integrity. Methods: We studied people with HIV (PWH) and HIV- individuals who had used cannabis [...]

Lire la suite

Expérimentation de l’usage médical du cannabis : poursuite des travaux – ANSM – Point d’Information 03/06/2020

Expérimentation de l’usage médical du cannabis : poursuite des travaux - Point d'Information 03/06/2020 Dans la continuité des travaux menés depuis 2018, la Direction générale de la santé (DGS) et l’ANSM restent pleinement engagés dans mise en place de l’expérimentation de l’usage médical du cannabis en France. Cependant, en raison de la nécessaire mobilisation des autorités de santé sur la gestion de l’épidémie de COVID-19, le début de l’expérimentation, initialement prévu en septembre 2020 est reporté au plus tard en janvier 2021. Conduits en concertation avec les membres du Comité scientifique de l’ANSM et les sociétés savantes concernées, les travaux pour la prochaine [...]

Lire la suite

Impact of COVID-19 on drug services and help-seeking in Europe, EMCDDA trendspotter briefing, May 2020

Impact of COVID-19 on drug services and help-seeking in Europe EMCDDA trendspotter briefing May 2020   The situation regarding public health responses to the COVID-19 pandemic is rapidly evolving. Up-to-date information can be found in the guidelines prepared by national public health sources and the regular updates from the European Centre for Disease Prevention and Control and the World Health Organization. The EMCDDA has created a COVID-19 resource hub for people who use drugs and drug service providers. Summary Since the start of 2020, European countries have been experiencing an unprecedented public health threat with the emergence of the coronavirus disease (COVID-19). In order to investigate [...]

Lire la suite

Le National favorable aux tests de distribution de cannabis bio Mardi, Dépêche ATS Berne, 02 juin 2020

Le National favorable aux tests de distribution de cannabis bio Mardi, 02 juin 2020 Dépêche ATS Berne   Des tests de distribution de cannabis récréatif biologique devraient avoir lieu en Suisse. Le National y est favorable. Il a précisé mardi les contours de ces expériences qui pourraient être menées dans de grandes villes helvétiques. En décembre, la Chambre du peuple, dans sa nouvelle composition, avait accepté d'entrer en matière sur cette modification de la loi sur les stupéfiants contre l'avis de sa commission. Celle-ci a dû revoir sa copie et s'est ralliée dans les grandes lignes au projet du gouvernement. Le dossier n'a pas [...]

Lire la suite